Publications by authors named "Devin Mutha"
Allogeneic chimeric antigen receptor (CAR) T cell therapies hold the potential to overcome many of the challenges associated with patient-derived (autologous) CAR T cells. Key considerations in the development of allogeneic CAR T cell therapies include prevention of graft-vs-host disease (GvHD) and suppression of allograft rejection. Here, we describe preclinical data supporting the ongoing first-in-human clinical study, the CaMMouflage trial (NCT05722418), evaluating CB-011 in patients with relapsed/refractory multiple myeloma.
View Article and Find Full Text PDFWNTs are essential factors for stem cell biology, embryonic development, and for maintaining homeostasis and tissue repair in adults. Difficulties in purifying WNTs and their lack of receptor selectivity have hampered research and regenerative medicine development. While breakthroughs in WNT mimetic development have overcome some of these difficulties, the tools developed so far are incomplete and mimetics alone are often not sufficient.
View Article and Find Full Text PDFArticle Synopsis
- The Wnt signaling pathway plays a critical role in regulating bone mass in both humans and rodent models, and researchers have developed a new antibody-based platform to create effective Wnt mimetics.
- These engineered bi-specific Wnt mimetics target specific proteins to enhance bone growth in mice, demonstrating significant improvements in various bone-related conditions like osteoporosis and fractures.
- Combining these Wnt mimetics with existing treatments like bisphosphonates enhances bone accrual, suggesting their potential for treating conditions related to low bone mineral density.